News | June 15, 2010

Trial Finds Aneurysm Size Does Not Affect Outcome After EVAR

June 15, 2010 – Patients with smaller abdominal aortic aneurysms (AAAs) (less than 5.5 cm) have no significant differences in clinical outcomes after endovascular repair (EVAR) than those with larger AAAs according to data from a five-year prospective clinical trial setting. The researchers maintain their recommendation that small aneurysms should not be treated surgically. Details of this study were presented at the 64th Vascular Annual Meeting hosted the Society for Vascular Surgery.

Researchers from the Washington University School of Medicine in St. Louis reported data from a subgroup analysis of the prospective Medtronic Talent Enhanced Low Profile System trial. There were no statistically significant differences in the rate of freedom from major adverse events (84.6 percent versus 75.8 percent) or freedom from aneurysm-related mortality (98.7 percent versus 96.8 percent) at one year. Long-term outcomes at five years also showed no difference.

Jeffrey Jim, M.D., a fellow from the section of vascular surgery, said that 156 patients enrolled in the prospective Medtronic Talent Enhanced Low Profile System trial were evaluated. Analyses were performed for patients with AAAs that measured less than 5.5 cm and for those with AAAs larger than 5.5 cm. Demographics, aneurysm morphology, and perioperative endpoints were assessed. Safety and effectiveness endpoints were evaluated at 30 days, one year, and five years after the procedures.

"All patients in the study (85 small AAAs and 71 large) had similar age, gender and medical risk profile," Jim said. "However, there were anatomic differences between the two group with the aortic neck in small AAA patients being longer (24.7 mm vs 20.7 mm), less angulated (27.20 vs 34.20) and smaller (24.6 mm vs 26.1 mm). In terms of perioperative outcomes, the two groups were very similar with the only difference being the small AAA patients spent less time in the intensive care unit (8.1 hours vs 26.3 hours). The small AAA patients also had higher rate of successful aneurysm treatment at 12 months (96.8 vs 84.9 percent) as defined by the study as the combination of technical success, absence of aneurysm expansion, and absence of reintervention for type I or type III endoleaks."

Jim added that there were no other statistically significant differences during the perioperative period or any other effectiveness endpoints at 12 months. There were also no differences in rates of migration, endoleaks, change in aneurysm diameter or freedom from aneurysm-related mortality at five years.

"We even did further subgroup analyses by separating groups by AAA centimeter size: 55 patients with very small (less than 5 cm), 30 with small (5.1-5.4 cm), and 71 with larger (more than 5.5 cm). The findings were similar to our original comparison," Jim said. "The data from this study is unique in that it comes from a prospective five-year clinical trial. The results confirm the intuitive notion that smaller AAAs have aortic neck characteristics that are more favorable for EVAR. However, the important take home message is that there were no differences in long-term five-year outcomes between the two groups. So our position remains that EVAR should not be routinely recommended for those with small AAAs."

For more information: www.VascularWeb.org.

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo